Anascorp market report points to demand from envenomation cases and healthcare spending

The Business Research Company says Anascorp demand is rising as scorpion envenomation, snakebite treatment needs and healthcare spending increase. The report also flags North America as the biggest market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Anascorp is an antivenom used for severe scorpion sting reactions, so demand tracks emergency care needs and venom exposure risk. - The market report points to wider public health pressure from venomous animal encounters, faster access to treatment, and stronger preparedness for toxicology emergencies. - A larger antivenom market can affect hospital stocking decisions, emergency department readiness and biologics supply planning.

What happened: - The Business Research Company released an Anascorp market insights report on Oct. 29, 2026. - The report examines market size, growth drivers, emerging trends and regional outlook for the Anascorp segment. - The report says North America held the largest share of the Anascorp market in 2025. - The report projects Asia-Pacific will be the fastest-growing region during the forecast period. - Download the full report

The details: - Anascorp is a biopharmaceutical antivenom designed to treat toxic effects from scorpion stings, especially from dangerous Centruroides species. - The report links historical growth to scorpion envenomation cases, more emergency department visits, antivenom effectiveness, government stockpiling initiatives and regional differences in venom exposure risk. - The report says future growth will be driven by climate-related spread of venomous species, better emergency healthcare access, more trauma centers, higher public health funding and greater awareness of venom treatment protocols. - The report identifies sustained antivenom demand, hospital-based emergency toxicology services, region-specific envenomation treatment, cold chain management for biologics and public health preparedness as key trends. - The report says rising snakebite incidents are a major growth driver because Anascorp can help neutralize venom from certain snake species and reduce severe symptoms, organ damage and fatalities. - The World Health Organization reported in September 2023 that about 5.4 million snakebites occur annually worldwide, causing 81,410 to 137,880 deaths and many permanent disabilities. - The report also ties market growth to rising infectious disease prevalence, which can worsen healthcare burdens and strengthen demand for effective emergency treatment. - The UK Health Security Agency reported in February 2024 that tuberculosis cases in England rose 10.7% in 2023 from the prior year. - The report says higher healthcare spending supports access to antivenom therapy and improvements in emergency care infrastructure. - The Office for National Statistics reported in May 2024 that total UK healthcare expenditure rose 5.6% nominally in 2023, or 0.9% more than in 2022. - The report includes new 2026 analytics features such as market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and a full version through the company's website: More information

Between the lines: - The report frames Anascorp as part of a broader emergency medicine and biologics market, not just a niche antivenom product. - The growth narrative relies on external public health trends, especially venom exposure risk, healthcare capacity and emergency preparedness. - North America's lead suggests established treatment access, while faster growth in Asia-Pacific points to expanding demand where venom-related risks and healthcare investment may be rising.

What's next: - The market report expects continued demand for antivenom therapies as venomous species spread and emergency systems improve. - Hospitals and public health systems are likely to keep focusing on stocking, cold chain logistics and treatment protocols for venom incidents. - The company's report positions future market growth around better preparedness for region-specific envenomation cases and stronger trauma and toxicology infrastructure.